BioSpace News Archive

Study results demonstrate that LUPKYNIS in combination with typical standard of care (SoC) led to statistically superior complete renal response rates compared to treatment with SoC alone

So-Young International Inc., the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, announced that it will report its financial results for the first quarter ended March 31, 2021, before U.S. markets open on May 19, 2021.

BioNTech SE a next generation immunotherapy company pioneering novel therapies for cancer and infectious diseases, provided an update on its corporate progress and reported financial results for the quarter ended March 31, 2021.

Study to determine safety and tolerability of CBX-12 and establish recommended Phase 2 dose

Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system disorders, reported financial results for the first quarter ended March 31, 2021.

Viatris Inc. reported results for the first quarter of 2021, which demonstrate the strength of its differentiated operating platform and commercial capabilities, its broad and diverse product portfolio and its strong R&D platform.

The Infectious Disease Research Institute, Duke Human Vaccine Institute, and 3M have collaborated to create a vaccine candidate with potential to provide protection against multiple variants of SARS-CoV-2, as well as other coronaviruses.

Transit Scientific announced it received CE Mark clearance in the European Union for the XO Score® Scoring Sheath Platform to facilitate dilation of stenotic material in the peripheral vasculature including popliteal, infrapopliteal, and native or synthetic arteriovenous dialysis fistulae.

Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, announced it has appointed Anne McGeorge, M.S., CPA, to its Board of Directors, and as Audit Committee Chair.

Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer, announced it will be presenting at several upcoming scientific congresses in May and June.